(Q35872344)

10 August 2017

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study (English)

1 reference

clinically isolated syndrome

10 August 2017

1 reference

16

P A Calabresi

1 reference

10 August 2017

1

E Waubant

1 reference

10 August 2017

Bianca Weinstock-Guttman

15

object named as

B Weinstock-Guttman

1 reference

10 August 2017

D Pelletier

2

1 reference

10 August 2017

M Mass

3

1 reference

10 August 2017

J A Cohen

4

1 reference

10 August 2017

M Kita

5

1 reference

10 August 2017

A Cross

6

1 reference

10 August 2017

A Bar-Or

7

1 reference

10 August 2017

T Vollmer

8

1 reference

10 August 2017

M Racke

9

1 reference

10 August 2017

O Stüve

10

1 reference

10 August 2017

S Schwid

11

1 reference

10 August 2017

A Goodman

12

1 reference

10 August 2017

N Kachuck

13

1 reference

10 August 2017

J Preiningerova

14

1 reference

10 August 2017

A Miller

17

1 reference

10 August 2017

M Mokhtarani

18

1 reference

10 August 2017

D Iklé

19

1 reference

10 August 2017

S Murphy

20

1 reference

10 August 2017

H Kopetskie

21

1 reference

10 August 2017

L Ding

22

1 reference

10 August 2017

E Rosenberg

23

1 reference

10 August 2017

C Spencer

24

1 reference

10 August 2017

S S Zamvil

25

1 reference

10 August 2017

ITN STAyCIS Study Group

26

1 reference

10 August 2017

ITN020AI Study Management Team

27

1 reference

10 August 2017

language of work or name

English

0 references

publication date

28 March 2012

1 reference

10 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Neurology

1 reference

10 August 2017

78

1 reference

10 August 2017

15

1 reference

10 August 2017

1171-1178

1 reference

Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Normalized accurate measurement of longitudinal brain change

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320055

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22459680

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22459680

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E31824F7FDD

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22459680

1 reference